Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Clin Cancer Res. 2016 Oct 19;22(21):5204–5210. doi: 10.1158/1078-0432.CCR-16-1241

Table 4.

Response

Cohort 1A 2A 3A 4A 1B 2B 3B All treatment
groups
N 3 3 8 3 3 4 3 27
Best overall response, n (%) CR 0 1 (33.3) 0 0 0 0 0 1 (3.7)
PR 0 0 0 0 0 0 0 0
SD 0 2 (66.7) 2 (25.0) 0 1 (33.3) 2 (50.0) 3 (100.0) 10 (37.0)
Non-CR/Non-
PD* 		1 (33.3) 0 0 0 0 0 0 1 (3.7)
PD 2 (66.7) 0 5 (62.5) 2 (66.7) 2 (66.7) 1 (25.0) 0 12 (44.4)
Not Evaluable 0 0 1 (12.5) 1 (33.3) 0 1 (25.0) 0 3 (11.1)
Disease control rate
(CR+PR+SD)		 0.00% 100.00% 25.00% 0 33.30% 50 100.00% 40.70%
95% CI (%) 0.0,
70.8		 29.2,
100.0		 3.2,
65.1		 0.0,
70.8		 0.8,
90.6		 6.8,
93.2		 29.2,
100.0		 22.4, 61.2
p-value 0.1000
*

One patient in this cohort had nontarget disease only, and as per protocol was characterized as Non-CR/Non-PD